Safety, pharmacokinetics, and pharmacodynamics of single doses of lxr-623, a novel liver X-receptor agonist, in healthy participants

Journal of Clinical Pharmacology

Volumn 49, Issue 6, 2009, Pages 643-649

  Katz, Arie ^a,b   Udata, Chandrasekhar ^a   Ott, Elyssa ^a   Hickey, Lisa ^a   Burczynski, Michael E ^a   Burghart, Peter ^a   Vesterqvist, Ole ^a   Meng, Xu ^a  

^a PFIZER INC   (United States)

^b Clinical Translational Medicine Wyeth Pharmaceuticals ^*  (United States)

Author keywords

ABCAl; ABCGl; ATP bindingcassettes; Liver X receptor (LXR); Population pharmacokinetics and pharmacodynamics; Reverse cholesterol transport(RCT)

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; LIVER X RECEPTOR AGONIST; LXR 623; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SINUS TACHYCARDIA;

EID: 67049144914     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009335768     Document Type: Article

References (29)

1. Repa JJ, Turley SD, Lobaccaro JA, et al. Regulation of absorption and ABCl-mediated efflux of cholesterol by RXR heterodimers. Science. 2000;289:1524-1529.
2. Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis. Genes Dev. 2000;14:2831-2838.
3. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent trans-activation of the ABCl promoter by the liver X receptor/retinoid X receptor. J Biol Chem. 2000;275:28240-28245.
4. Laffitte BA, Repa JJ, Joseph SB, et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA. 2001;98:507-512.
5. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest. 2000;105:513-520.
6. Schwartz K, Lawn RM, Wade DP. ABCl gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem Biophys Res Commun. 2000;274:794-802.
7. Venkateswaran A, Laffitte BA, Joseph SB, et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA. 2000;97:12097-12102.
8. Venkateswaran A, Repa JJ, Lobaccaro JM, Bronson A, Mangelsdorf DJ, Edwards PA. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages: a tran-scriptional role for specific oxysterols. J Biol Chem. 2000;275: 14700-14707.
9. Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters [see comment]. Science. 2000;290:1771-1775.
10. Bodzioch M, Orso E, Klucken J, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease [see comment]. Nat Genet. 1999;22:347-351.
11. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABCl in Tangier disease and familial high-density lipoprotein deficiency [see comment]. Nat Genet. 1999;22:336-345.
12. Groot PH, Pearce NJ, Yates JW, et al. Synthetic LXR agonists increase LDL in CETP species. J Lipid Res. 2005;46:2182-2191.
13. Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem. 2002;277:18793-18800.
14. Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 [see comment]. Nat Genet. 1999;22:352-355.
15. Wouters K, Shiri-Sverdlov R, van Gorp PJ, van Bilsen M, Hofker MH. Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. Clin Chem Lab Med. 2005:43:470-479.
16. Koldamova R, Lefterov I. Role of LXR and ABCAl in the pathogenesis of Alzheimer's disease: implications for a new therapeutic approach. Curr Alzheimer Res. 2007;4:171-178.
17. Riddell DR, Zhou H, Comery TA, et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci. 2007)34:621-628.
18. Nambi P, Basso MD, Chen L, et al. LXR-623, a novel liver X receptor modulator, displays neutral lipid effects in cholesteryl ester transfer protein-expressing species and inhibits atherosclerotic lesion progression in low density lipoprotein receptor knockout mice. Circulation. 2007;116:II-299.
19. Quinet E, Basso MD, Halpern AR, et al. A novel LXR ligand reduces LDL cholesterol in monkey. Circulation. 2007;116:II-106.
20. DiBlasio-Smith EA, Quinet EM, Nambi P, et al. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J Transl Med. 2008;6:59-73.
21. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of PK and PD: application to d-tbocurarine. Clin Pharmacol Ther. 1979;25:358-371.
22. Cao G, Bales KR, DeMattos RB, Paul SM. Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics. Curr Alzheimer Res. 2007;4:179-184.
23. Koldamova RP, Lefterov IM, Staufenbiel M, et al. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem. 2005:280:4079-4088.
24. Fukumoto H, Deng A, Irizarry MC, Fitzgerald ML, Rebeck GW. Induction of the cholesterol transporter ABCAl in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. J Biol Chem. 2002;277:48508-48513.
25. Burns MP, Vardanian L, Pajoohesh-Ganji A, et al. The effects of ABCAl on cholesterol efflux and Abeta levels in vitro and in vivo. J Neurochem. 2006:98:792-800.
26. Rebeck GW. Cholesterol efflux as a critical component of Alzheimer's disease pathogenesis. J Mol Neurosci. 2004;23: 219-224.
27. Sun Y, Yao J, Kim TW, Tall AR. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J Biol Chem. 2003:278:27688-27694.
28. Whitney KD, Watson MA, Collins JL, et al. Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol Endocrinol. 2002:16:1378-1385.
29. Adighibe O, Arepalli S, Duckworth J, Hardy J, Wavrant-De Vrieze F. Genetic variability at the LXR gene (NR1H2) may contribute to the risk of Alzheimer's disease. Neurobiol Aging. 2006:27:1431-1434.